Savira Pharma, Roche licensing deal covers inhibition of influenza polymerase
This article was originally published in Scrip
Executive Summary
The Austrian drug development company, Savira Pharmaceuticals, has granted Roche exclusive, worldwide rights to a small molecule programme where the goal is to use inhibition of the influenza polymerase as a promising target for novel anti-influenza drugs. Savira, founded in 2009, will receive an undisclosed upfront payment and research and development support, and is eligible for up to EUR240 million in milestones, plus royalties.